ESOPJun 2, 2026, 04:07 PM
Forte Biosciences Stockholders Approve Amended 2021 Equity Plan
AI Summary
Forte Biosciences, Inc. stockholders approved the Amended and Restated 2021 Equity Incentive Plan at the 2026 Annual Meeting. This plan reserves 5,190,000 newly requested shares, plus up to 44,093 shares from previous plans, to attract and retain personnel through various equity grants. Additionally, stockholders elected three Class III directors, ratified KPMG LLP as the independent auditor for 2026, and approved, on an advisory basis, the compensation of named executive officers for fiscal year 2025.
Key Highlights
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan.
- The plan reserves 5,190,000 newly requested shares for issuance.
- Up to 44,093 shares from prior plans can also be added to the new plan.
- Steven Kornfeld, Scott Brun, M.D., and Paul A. Wagner, Ph.D. were elected as Class III directors.
- KPMG LLP was ratified as the independent auditor for fiscal year 2026.
- Executive compensation for fiscal year 2025 was approved on an advisory basis.
Price Impact
More from FBRX